Inhibition of DYRK1a Enhances Cardiomyocyte Cycling After Myocardial Infarction.

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Regenerative Medicine

Background:

• Dual-specificity tyrosine phosphorylation-regulated kinase 1a (DYRK1a) plays a role in regulating cell cycles, including those of cardiomyocytes.
• The impact of DYRK1a inhibition on cardiac function and cardiomyocyte proliferation following myocardial infarction (MI) is not well understood.

Purpose of the Study:

• To investigate the effects of pharmacological inhibition and genetic ablation of DYRK1a on cardiomyocyte cycling and left ventricular function after ischemia-reperfusion myocardial infarction (I/R MI).
• To explore the therapeutic potential of targeting DYRK1a in the context of cardiac injury.

Main Methods:

• Utilized pharmacological inhibition with harmine and conditional genetic ablation of DYRK1a in mouse models (αMHC-MerDreMer-Ki67p-RoxedCre::Rox-Lox-tdTomato-eGFP and αMHC-Cre::Fucci2aR::DYRK1a mice).
• Assessed left ventricular systolic function (ejection fraction) and cardiomyocyte proliferation (eGFP+ cells, hyperplasia) post-I/R MI.
• Employed RNA sequencing (RNAseq) to analyze gene expression in isolated cardiomyocytes.

Main Results:

• Harmine treatment improved left ventricular ejection fraction and increased cardiomyocyte cycling after I/R MI.
• Cardiomyocyte-specific genetic ablation of DYRK1a led to baseline hyperplasia and enhanced cardiac function post-I/R MI.
• RNAseq revealed enrichment of mitotic cell cycle genes in DYRK1a-deficient cardiomyocytes after I/R MI.

Conclusions:

• Pharmacological inhibition or genetic ablation of DYRK1a promotes cardiomyocyte proliferation and improves cardiac function following I/R MI.
• These findings highlight DYRK1a inhibition as a promising therapeutic strategy for treating myocardial infarction.